Aptevo Therapeutics Inc
Research Aptevo Therapeutics Inc (APVO) on Bullrun: market cap USD 2.96M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAPVO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.96M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 6.70M
- Free cash flow-USD 26.98M
Valuation Snapshot
latest market cap is USD 2.96M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 25.97M | -USD 25.59M | n/a | -87.27 | USD 21.62M | USD 4.63M | USD 17.38M |
| FY2024 | USD 0 | -USD 24.13M | -USD 23.79M | n/a | -31460.23 | USD 8.71M | USD 5.40M | USD 4.76M |
| FY2023 | n/a | -USD 17.41M | n/a | n/a | -2316.83 | USD 16.90M | USD 0 | USD 12.22M |
| FY2022 | USD 3.11M | USD 8.03M | -USD 21.05M | n/a | 1.57 | USD 22.64M | USD 3.46M | USD 17.97M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.96M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 8.83M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.36M | n/a | n/a | n/a |
| 2023 | 2023-06-29 | n/a | 139.1 | n/a | n/a |
| 2022 | 2022-12-30 | n/a | 676.3 | n/a | n/a |
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aptevo Therapeutics Inc's market cap?
Aptevo Therapeutics Inc's market capitalization is USD 2.96M.
What does Aptevo Therapeutics Inc do?
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia.